Research programme: neural regeneration peptides - CuroNZ

Drug Profile

Research programme: neural regeneration peptides - CuroNZ

Alternative Names: Neuro-regenerative peptides; Neuronal regeneration peptides; NNZ-4921; NRPs programme

Latest Information Update: 17 Oct 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Metabolic Pharmaceuticals; Neuren Pharmaceuticals
  • Developer CuroNZ
  • Class Nerve growth factors; Neuropeptides
  • Mechanism of Action Cell differentiation stimulants; CXCR4 receptor modulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; CNS disorders; Multiple sclerosis; Peripheral nervous system diseases; Retinal disorders; Spinal cord injuries

Most Recent Events

  • 17 Oct 2013 Preclinical development is ongoing in New Zealand
  • 17 Oct 2013 Research programme: neural regeneration peptides - CuroNZ is available for licensing as of 17 Oct 2013. http://www.curonz.com/
  • 31 Dec 2008 Preclinical trials in Amyotrophic lateral sclerosis in New Zealand (Parenteral) after 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top